SCANCELL HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.6 GBX | 0.00% |
|
0.00% | -8.57% |
| Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
| Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
Valuation
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 20.36 | 37.93 | 179.3 | 116.2 | 128.1 | 78.7 | - | - |
| Enterprise Value (EV) 1 | 15.8 | 34.35 | 153.4 | 95.62 | 108.9 | 82.58 | 93.65 | 102.1 |
| P/E ratio | -3.62 x | -6.74 x | -9.65 x | -57 x | -10.4 x | -5.34 x | -6.35 x | -6.37 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 24.3 x | - | - | - |
| EV / Revenue | - | - | - | - | 20.7 x | - | - | - |
| EV / EBITDA | -2.36 x | -5.1 x | -17.9 x | -7.61 x | -9.88 x | -4.79 x | -6.68 x | -7.24 x |
| EV / FCF | - | - | - | -8.34 x | -13.1 x | -5.66 x | -8.27 x | -9.43 x |
| FCF Yield | - | - | - | -12% | -7.66% | -17.7% | -12.1% | -10.6% |
| Price to Book | - | - | - | - | - | -7.31 x | -3.8 x | -2.5 x |
| Nbr of stocks (in thousands) | 387,797 | 465,356 | 815,219 | 815,219 | 818,403 | 819,823 | - | - |
| Reference price 2 | 0.0525 | 0.0815 | 0.2200 | 0.1425 | 0.1565 | 0.0960 | 0.0960 | 0.0960 |
| Announcement Date | 8/20/19 | 10/16/20 | 10/29/21 | 10/28/22 | 10/31/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 5.271 | - | - | - |
| EBITDA 1 | -6.708 | -6.739 | -8.585 | -12.56 | -11.02 | -17.23 | -14.01 | -14.11 |
| EBIT 1 | -6.729 | -6.782 | -8.834 | -13.3 | -11.92 | -18.03 | -14.86 | -14.94 |
| Operating Margin | - | - | - | - | -226.14% | - | - | - |
| Earnings before Tax (EBT) 1 | -6.714 | -6.768 | -16.8 | -3.768 | -14.3 | -15.82 | -16.32 | -16.72 |
| Net income 1 | -5.627 | -5.506 | -15.48 | -2.065 | -11.94 | -14.78 | -14.37 | -14.8 |
| Net margin | - | - | - | - | -226.45% | - | - | - |
| EPS 2 | -0.0145 | -0.0121 | -0.0228 | -0.002500 | -0.0150 | -0.0180 | -0.0151 | -0.0151 |
| Free Cash Flow 1 | - | - | - | -11.46 | -8.343 | -14.58 | -11.32 | -10.83 |
| FCF margin | - | - | - | - | -158.28% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/20/19 | 10/16/20 | 10/29/21 | 10/28/22 | 10/31/23 | - | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 3.88 | 14.9 | 23.4 |
| Net Cash position 1 | 4.56 | 3.58 | 25.9 | 20.5 | 19.2 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.2249 x | -1.066 x | -1.658 x |
| Free Cash Flow 1 | - | - | - | -11.5 | -8.34 | -14.6 | -11.3 | -10.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | - | -0.0100 | -0.0300 | -0.0400 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0 | 0.03 | 0.74 | 1.27 | 0.2 | 0.1 | 0.1 | - |
| Capex / Sales | - | - | - | - | 3.85% | - | - | - |
| Announcement Date | 8/20/19 | 10/16/20 | 10/29/21 | 10/28/22 | 10/31/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.096
GBP
Average target price
0.2473
GBP
Spread / Average Target
+157.64%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.57% | 98.03M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SCLP Stock
- Financials Scancell Holdings plc
